Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Quantitative PCR for Monitoring CML Patients 91<br />
11. Olavarria, E., Kanfer, E., Szydlo, R., et al. (2001) Early detection of BCR-ABL<br />
transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts<br />
outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.<br />
Blood 97, 1560–1565.<br />
12. Radich, J. P., Gooley, T., Bryant, E., et al. (2001) The significance of bcr-abl<br />
molecular detection in chronic myeloid leukemia patients “late,” 18 months or<br />
more after transplantation. Blood 98, 1701–1707.<br />
13. Merx, K., Muller, M. C., Kreil, S., et al. (2002) Early reduction of BCR-ABL<br />
mRNA transcript levels predicts cytogenetic response in chronic phase CML patients<br />
treated with imatinib after failure of interferon alpha. <strong>Leukemia</strong> 16, 1579–<br />
1583.<br />
14. Hughes, T. and Branford, S. (2003) Molecular monitoring of chronic myeloid<br />
leukemia. Semin. Hematol. 40, 62–68.<br />
15. Wang, L., Pearson, K., Ferguson, J. E., and Clark, R. E. (2003) The early molecular<br />
response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid<br />
leukaemia. Br. J. Haematol. 120, 990–999.<br />
16. Muller, M. C., Gattermann, N., Lahaye, T., et al. (2003) Dynamics of BCR-ABL<br />
mRNA expression in first-line therapy of chronic myelogenous leukemia patients<br />
with imatinib or interferon alpha/ara-C. <strong>Leukemia</strong> 17, 2392–2400.<br />
17. Hughes, T. P., Kaeda, J., Branford, S., et al. (2003) Frequency of major molecular<br />
responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic<br />
myeloid leukemia. N. Engl. J. Med. 349, 1423–1432.<br />
18. Paschka, P., Muller, M. C., Merx, K., et al. (2003) Molecular monitoring of response<br />
to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low<br />
levels of residual disease are associated with continuous remission. <strong>Leukemia</strong> 17,<br />
1687–1694.<br />
19. Branford, S., Rudzki, Z., Harper, A., et al. (2003) Imatinib produces significantly<br />
superior molecular responses compared to interferon alfa plus cytarabine in patients<br />
with newly diagnosed chronic myeloid leukemia in chronic phase. <strong>Leukemia</strong><br />
17, 2401–2409.<br />
20. Melo, J. V. (1997) BCR-ABL gene variants. Baillieres Clin. Haematol. 10, 203–222.<br />
21. Saglio, G., Guerrasio, A., Rosso, C., et al. (1990) New type of Bcr/Abl junction in<br />
Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 76,<br />
1819–1824.<br />
22. Pane, F., Frigeri, F., Sindona, M., et al. (1996) Neutrophilic-chronic myeloid leukemia:<br />
a distinct disease with a specific molecular marker (BCR/ABL with C3/<br />
A2 junction). Blood 88, 2410–2414.<br />
23. Branford, S., Rudzki, Z., and Hughes, T. P. (2000) A novel BCR-ABL transcript<br />
(e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with<br />
Philadelphia-positive chronic myeloid leukaemia. Br. J. Haematol. 109, 635–637.<br />
24. Okamoto, K., Karasawa, M., Sakai, H., Ogura, H., Morita, K., and Naruse, T.<br />
(1997) A novel acute lymphoid leukaemia type BCR/ABL transcript in chronic<br />
myelogenous leukaemia. Br. J. Haematol. 96, 611–613.
Change language